Merck takes aim at superbugs, to buy Cubist in $9.5 bln deal
December 08, 2014 at 07:10 AM EST
Dec 8 (Reuters) - Merck & Co Inc said on Monday it would buy Cubist Pharmaceuticals Inc in a deal valued at $9.5 billion, giving the major drugmaker an entry into the market for drugs that target so-called superbugs.
